SHELTON, Conn., Aug. 10, 2015 /PRNewswire/ -- NanoViricides,
Inc., (NYSE MKT: NNVC) (the "Company"), a nanomedicine company
developing anti-viral drugs, reports that the dramatic improvements
in clinical symptoms associated with herpes simplex virus infection
were reproduced in an animal model in a different laboratory. These
studies were performed by TransPharm Preclinical Solutions
("TransPharm"), a pre-clinical services company in Jackson, MI.
All of the nanoviricides® tested improved clinical scores
dramatically, with clinical presentation being arrested at redness
or simply raised local lesions, and a complete absence of
zosteriform spreading. All of the nanoviricides treated animals
survived the lethal HSV-1 infection challenge for the duration of
the study while untreated animals died towards the end of the
study. These nanoviricides are designed as topical treatment for
the breakout of herpes sores.
Some of the nanoviricides found effective in the previous study
were tested in this study for the confirmation of efficacy in a
dermal animal model in Balb-c mice using the same highly aggressive
and neurotropic HSV-1 strain H129c, which was used
previously.
The earlier studies were performed in the laboratory of Dr.
Ken S. Rosenthal at Northeast Ohio
Medical University where Dr. Rosenthal continued as a Professor
Emeritus. He is a leading researcher in herpes virus anti-viral
agents and vaccines.
In the previous study, two of the anti-Herpes nanoviricides®
reduced the extent of disease (morbidity) and mortality of the
HSV-1 infected animals that were treated. These nanoviricides also
reduced virus production in cell culture. Importantly,
topical dermal treatment with these nanoviricides led to almost
complete (>85%) survival of the infected mice in this animal
model whereas all untreated animals died of the disease. Further,
these nanoviricides were superior to topical treatment with an
acyclovir formulation employed as a positive control. The Company
reported on these studies in April, 2015.
Professor Rosenthal consulted with NanoViricides and TransPharm
for the establishment of the animal model for dermal HSV-1
infection using the HSV-1 strain H129c at the TransPharm
laboratories.
Existing therapies against HSV include acyclovir and drugs
chemically related to it. These drugs must be taken orally or
by injection and are not very effective as topical agents.
Other drugs are largely ineffective. Currently, there is no cure
for any of the herpesvirus infections.
About Dr. Rosenthal
Dr. Rosenthal is now Professor at
the Roseman University of Health Sciences College of Medicine,
NV. He continues as Professor Emeritus at Northeast Ohio
Medical University (NEOMED), after retiring in December 2014. He is a leading researcher in the
field of herpes viruses, antiviral drugs and vaccines. His research
interests encompass several aspects of how herpes simplex virus
(HSV) interacts with the host to cause disease. His research has
addressed how HSV infects skin cells and examined viral properties
that facilitate its virulence and ability to cause encephalitis. He
is also researching how the human host immune response works
against HSV for the development of protective and therapeutic
vaccines.
About TransPharm
Transpharm Preclinical Solutions
offer numerous types of studies for testing antimicrobials,
antivirals, antifungals, antiparasitics, along with newer therapies
using antibodies. TransPharm's scientists' skill set covers
a broad range of Research and Development. This allows us to offer
numerous services upon request. We have many strategic alliances
along the Biotechnology Corridor which allows us to offer a wide
variety of services.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-reports-that-the-dramatic-effects-of-its-topical-anti-herpes-treatment-were-reproduced-once-again-in-an-animal-model-in-a-different-laboratory-300125886.html
SOURCE NanoViricides, Inc.